Physician profile
Avinash Singh
NPI 1730383985
$9,356.17
in general payments reported to CMS, 2019-2025
44 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,677 · 2020: $1,126 · 2021: $958 · 2022: $1,355 · 2023: $1,572 · 2024: $1,332 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,024 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,024.10 |
| Education | $216.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,930.17 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,578.07 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.19 | 2019-2023 | Ofev |
| Amgen INC. | $548.37 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $547.20 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $479.20 | 2019-2025 | Xywav |
| Grifols USA, LLC | $432.25 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $304.76 | 2019-2025 | |
| Insmed, INC. | $283.68 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $245.31 | 2023-2024 | Wakix |
| Genentech USA, INC. | $231.79 | 2019-2025 | Xolair |
| Mylan Specialty L.P. | $206.41 | 2019-2024 | Yupelri |
| Boston Scientific Corporation | $175.10 | 2022-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $165.83 | 2019-2023 | |
| Philips North America LLC | $164.43 | 2019-2025 | Patient Interface Software |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $138.36 | 2019-2023 | Opsumit, Uptravi |
| United Therapeutics Corporation | $128.26 | 2020-2023 | Tyvaso, Orenitram |
| Scpharmaceuticals INC. | $125.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.25 | 2020-2025 | Glassia |
| Abiomed | $99.06 | 2024 | Impella |
| Edwards Lifesciences Corporation | $90.95 | 2025 | |
| Sunovion Pharmaceuticals INC. | $90.89 | 2019 | |
| Terumo Medical Corporation | $64.20 | 2024 | Heartrail, Angio-Seal, Optitorque |
| Electromed, INC. | $63.91 | 2019-2022 | |
| Advanced Respiratory, INC | $63.04 | 2019-2021 | |
| Aerin Medical INC. | $59.81 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $52.85 | 2021 | |
| Viatris Specialty LLC | $42.83 | 2025 | Yupelri |
| Novo Nordisk INC | $42.56 | 2023 | Wegovy |
| Gilead Sciences, INC. | $41.10 | 2019 | |
| Shire North American Group INC | $39.98 | 2019 | |
| Baxter Healthcare | $36.28 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Circassia INC. | $28.62 | 2019 | |
| Cvrx, INC. | $27.68 | 2022 | |
| Checkpoint Surgical, INC | $25.44 | 2024 | Checkpoint Stimulators |
| Abbvie INC. | $22.85 | 2023 | |
| Pulmonx Corporation | $22.31 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.52 | 2024 | Acthar |
| Integra Lifesciences Corporation | $20.19 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Apria Healthcare LLC | $16.55 | 2021 | |
| Allergan, INC. | $14.07 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.55 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $13.30 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.